NASDAQ:CRBP - Corbus Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$7.53 -0.07 (-0.92 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$7.53
Today's Range$7.35 - $7.75
52-Week Range$4.50 - $9.95
Volume739,032 shs
Average Volume1.04 million shs
Market Capitalization$435.01 million
P/E Ratio-11.58
Dividend YieldN/A
Beta2.11

Headlines

Corbus Pharmaceuticals (NASDAQ CRBP) News Headlines

Source:
DateHeadline
$1.99 Million in Sales Expected for Corbus Pharmaceuticals Holdings Inc (CRBP) This Quarter$1.99 Million in Sales Expected for Corbus Pharmaceuticals Holdings Inc (CRBP) This Quarter
www.americanbankingnews.com - January 12 at 3:04 AM
Noteworthy Friday Option Activity: ABMD, HAS, CRBPNoteworthy Friday Option Activity: ABMD, HAS, CRBP
www.nasdaq.com - January 11 at 4:25 PM
Corbus Pharma up 11% premarketCorbus Pharma up 11% premarket
seekingalpha.com - January 11 at 11:04 AM
Corbus Pharmaceuticals (CRBP) Stock Rating Reaffirmed by Cantor FitzgeraldCorbus Pharmaceuticals (CRBP) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - January 11 at 9:01 AM
-$0.22 EPS Expected for Corbus Pharmaceuticals Holdings Inc (CRBP) This Quarter-$0.22 EPS Expected for Corbus Pharmaceuticals Holdings Inc (CRBP) This Quarter
www.americanbankingnews.com - January 10 at 5:18 PM
Corbus And Inventiva In Systemic Sclerosis: Looking Good - Seeking AlphaCorbus And Inventiva In Systemic Sclerosis: Looking Good - Seeking Alpha
seekingalpha.com - January 8 at 10:32 AM
Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock OptionsImplied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
finance.yahoo.com - January 7 at 10:32 AM
Corbus Pharmaceuticals Holdings Inc (CRBP) Receives Consensus Rating of "Buy" from BrokeragesCorbus Pharmaceuticals Holdings Inc (CRBP) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 7 at 3:34 AM
Kaken PharmaceuticalKaken Pharmaceutical
www.benzinga.com - January 4 at 8:58 AM
HC Wainwright Reiterates "Buy" Rating for Corbus Pharmaceuticals (CRBP)HC Wainwright Reiterates "Buy" Rating for Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - January 4 at 7:25 AM
Corbus Pharma up 6% on Kaken collaborationCorbus Pharma up 6% on Kaken collaboration
seekingalpha.com - January 3 at 3:59 PM
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and DermatomyositisCorbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
finance.yahoo.com - January 3 at 10:41 AM
Notable Monday Option Activity: AMZN, BKNG, CRBPNotable Monday Option Activity: AMZN, BKNG, CRBP
www.nasdaq.com - January 1 at 9:53 AM
Stock Traders Purchase High Volume of Call Options on Corbus Pharmaceuticals (CRBP)Stock Traders Purchase High Volume of Call Options on Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - January 1 at 7:22 AM
Corbus Pharma, Neurometrix surge as H.C. Wainwright starts at BuyCorbus Pharma, Neurometrix surge as H.C. Wainwright starts at Buy
seekingalpha.com - December 26 at 4:03 PM
HC Wainwright Bullish On Corbus Therapeutics Cystic Fibrosis OpportunityHC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity
finance.yahoo.com - December 26 at 4:03 PM
Corbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at HC WainwrightCorbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - December 26 at 7:34 AM
Corbus Pharma up 3% premarket on new lenabasumm patentCorbus Pharma up 3% premarket on new lenabasumm patent
seekingalpha.com - December 18 at 4:08 PM
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum - GlobeNewswireCorbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum - GlobeNewswire
www.globenewswire.com - December 18 at 10:41 AM
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to LenabasumCorbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
finance.yahoo.com - December 18 at 10:41 AM
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis - GlobeNewswireCorbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis - GlobeNewswire
globenewswire.com - December 17 at 10:44 AM
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in DermatomyositisCorbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
finance.yahoo.com - December 17 at 10:44 AM
RBC sees a three-bagger in Corbus PharmaRBC sees a three-bagger in Corbus Pharma
seekingalpha.com - December 7 at 9:57 AM
Some of Decembers Most Interesting StocksSome of December's Most Interesting Stocks
finance.yahoo.com - December 4 at 10:24 AM
Analyzing 22nd Century Group’s Year-to-Date PerformanceAnalyzing 22nd Century Group’s Year-to-Date Performance
finance.yahoo.com - November 12 at 10:10 AM
How Marijuana-Focused Biotech Companies Have Performed in 2018How Marijuana-Focused Biotech Companies Have Performed in 2018
finance.yahoo.com - November 9 at 3:59 PM
Corbus Pharmaceuticals Holdings, Inc (CRBP) CEO Yuval Cohen on Q3 2018 Results - Earnings Call TranscriptCorbus Pharmaceuticals Holdings, Inc (CRBP) CEO Yuval Cohen on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 9 at 10:30 AM
Edited Transcript of CRBP earnings conference call or presentation 8-Nov-18 1:30pm GMTEdited Transcript of CRBP earnings conference call or presentation 8-Nov-18 1:30pm GMT
finance.yahoo.com - November 9 at 10:30 AM
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Misses Revenue EstimatesCorbus Pharmaceuticals (CRBP) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 8 at 4:00 PM
BRIEF-Corbus Pharmaceuticals Q3 Loss Per Share $0.26BRIEF-Corbus Pharmaceuticals Q3 Loss Per Share $0.26
www.msn.com - November 8 at 10:10 AM
Corbus Pharmaceuticals: 3Q Earnings SnapshotCorbus Pharmaceuticals: 3Q Earnings Snapshot
finance.yahoo.com - November 8 at 10:10 AM
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business UpdateCorbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - November 8 at 10:10 AM
How Much Of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Do Insiders Own?How Much Of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Do Insiders Own?
finance.yahoo.com - November 6 at 3:55 PM
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in NovemberCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
finance.yahoo.com - November 6 at 10:09 AM
Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
finance.yahoo.com - November 5 at 3:56 PM
New Data From Corbus For Lenabasum In Scleroderma Favors Approval Come 2020New Data From Corbus For Lenabasum In Scleroderma Favors Approval Come 2020
seekingalpha.com - October 29 at 9:17 AM
Corbus Pharma (CRBP) Reports Lenabasum Long-Term Open-Label Clinical Data in Systemic Sclerosis and Dermatomyositis Phase 2 StudiesCorbus Pharma (CRBP) Reports Lenabasum Long-Term Open-Label Clinical Data in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
www.streetinsider.com - October 24 at 10:01 AM
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of ...Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of ...
globenewswire.com - October 22 at 3:48 PM
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 StudiesCorbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
finance.yahoo.com - October 22 at 10:19 AM
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic ...Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic ...
globenewswire.com - October 19 at 10:15 AM
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis ConferenceCorbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
finance.yahoo.com - October 19 at 10:15 AM
Stocks Jump 2%+ on Solid EarningsStocks Jump 2%+ on Solid Earnings
finance.yahoo.com - October 17 at 9:49 AM
Corbus Pharma (CRBP) Announces Patent Issuance Covering Use of LenabasumCorbus Pharma (CRBP) Announces Patent Issuance Covering Use of Lenabasum
www.streetinsider.com - October 3 at 3:49 PM
Corbus Pharmaceuticals announces patent issuance covering use of Lenabasum for the treatment of fibrotic diseasesCorbus Pharmaceuticals announces patent issuance covering use of Lenabasum for the treatment of fibrotic diseases
seekingalpha.com - October 3 at 9:55 AM
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
finance.yahoo.com - October 3 at 9:55 AM
Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% HigherAdamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher
www.msn.com - September 27 at 10:04 AM
Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% HigherCorbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher
finance.yahoo.com - September 27 at 10:04 AM
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in OctoberCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
finance.yahoo.com - September 26 at 10:36 AM
Cramer’s Exec Cut: Bringing the cannabis craze down to ea...Cramer’s Exec Cut: Bringing the cannabis craze down to ea...
finance.yahoo.com - September 22 at 9:59 AM
Why Corbus Pharmaceuticals Holdings Inc. Tumbled TodayWhy Corbus Pharmaceuticals Holdings Inc. Tumbled Today
www.fool.com - September 21 at 1:34 PM
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel